Rigel Pharmaceuticals (RIGL) closed the last trading session at $17.35, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Average stars like our sun die ignominiously. They swell to enormous size, cool from yellow to red hot, and shed most of ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...

M, including: Net product sales of approximately $185M-$192M; Contract revenues from collaborations of approximately $15M-$18M. The company anticipates it will report positive net income for the full ...

Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...